A Little-Known Law Gave Birth to Google -- and Countless Other Inventions


By Katharine Ku

When Google founders Larry Page and Sergey Brin spoke to my colleagues at Stanford's technology licensing office in the late 1990s, other search engines already existed.

But Page and Brin, who were graduate students at the time, believed the page-rank algorithm they had developed at Stanford was superior, even though no other entrepreneurs saw its potential. So they decided to launch a start-up. The Stanford licensing office saw merit in their idea and licensed the algorithm -- which was owned by the University -- back to the entrepreneurs. The rest is history.

It's unlikely Google would have become the world's most popular search engine without the sorts of patent protections provided by the Bayh-Dole Act, a little-known law passed in 1980. In fact, over the past 40 years, Bayh-Dole has given rise to some of our nation's most revolutionary innovations.

Universities are the birthplace of this innovation. But prior to Bayh-Dole, just a small fraction of government-funded university research initiatives ever saw the light of day. That's because the federal government retained patents that resulted from this research -- and did a poor job of licensing the patents to private firms that could turn academic discoveries into real-world products. In fact, fewer than 5 percent of all federally-funded research patents were licensed commercially.

That was bad for everyday Americans, who weren't seeing many tangible products result from the research programs funded by their tax dollars. In December 1980, the Bayh-Dole Act broke this logjam by empowering many universities, to maintain ownership of their patented inventions and commercially license them.

That enabled institutions to create a system for academics to license their discoveries. And it enabled businesses to raise the capital for follow-on research that turned discoveries into real-life products.

Bayh-Dole has yielded significant benefits for the broader U.S. economy. From 1996 to 2017, academic technology transfers generated up to $1.7 trillion in U.S. gross industrial output, according to AUTM, a non-profit that supports academic research. The law has supported nearly 6 million jobs and helped launch more than 13,000 start-ups. And it has spurred the development of over 200 new medicines.

Critics of Bayh-Dole claim that federal funding drives much of America's innovation, and that private companies reap the rewards while taking minimal risks. But that's not true. Tech transfer is still enormously risky. Even with Bayh-Dole, it's still quite difficult to commercialize many academic innovations.

As the law approaches its 40th anniversary, it's time for consumers and policymakers alike to recognize Bayh-Dole as the driving force behind so many of our most ingenious inventions. We need to protect Bayh-Dole now more than ever to foster even greater innovations in the future

Katharine Ku, the chief licensing advisor in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, served as the executive director of Stanford University's Office of Technology Licensing for 27 years. This piece originally ran at The Mercury News.

More Resources


04/23/2024
Groupthink Chorus Emerges at Trump Trial
Covering former President Donald Trump's trial on television is a difficult job.

more info


04/23/2024
Can Down-Ballot Races Lift Biden to Victory in 2024?
When you have a presidential candidate who is struggling to generate enthusiasm in the party base, it's natural to look for some external stimulation.

more info


04/23/2024
Biden Should Step Aside, Only Kennedy Can Beat Trump
And because Kennedy is the only candidate who can beat Donald Trump

more info


04/23/2024
Speaker Johnson Got 'Swamped' Over Ukraine
The return of GOP's minority-party mindset is very likely to be a self-fulfilling prophecy come November.

more info


04/23/2024
How Ukraine Wins
It took far too long, but House Speaker Mike Johnson showed true leadership in bringing Ukraine aid to a vote.

more info


04/23/2024
Leadership Lied, Said Border Funding Before Ukraine Aid
Florida Republican Rep. Byron Donalds told CNBC on Monday that the MAGA supporters who attempted to tie border security funding to military aid for Ukraine were lied to.

more info


04/23/2024
A Bipartisan House?
In my last dispatch, I described the Speaker of the House Mike Johnson as looking like an overmatched pharmacist. Well, he still looks like a pharmacist-but his mildness of affect has brought forth mighty victories in recent days, not just on aid to Ukraine, but also on surveillance funding (the FISA court) and various other spending bills, including the national security appropriation (which passed thanks to pressure from my friends in the bipartisan military caucus, For Country). So I was wrong to call him overmatched.

more info


04/23/2024
The Secret Force Defending American Principles
The commentary class was collectively shocked when new polling this week showed over 90% of Americans across the political spectrum share core principles. More specifically, the vast majority firmly believe in the importance of fundamental freedoms such as the right to vote, equal protection under the law, freedom of speech, and freedom of religion.

more info


04/23/2024
Who's Behind the Anti-Israel Protests
Hamas, Hezbollah, the Houthis and others are grooming activists in the U.S. and across the West.

more info


04/23/2024
The Coming Arab Backlash
Middle Eastern regimes-and America-ignore public anger at their peril

more info


04/23/2024
I Was Stabbed in the Eye at Yale
The school has allowed anti-Israel students to run roughshod over their most basic policies. Yesterday, I paid the price for their inaction.

more info


04/23/2024
Rising Antisemitism and Choosing Freedom
This weekend at Columbia and Yale, student demonstrators told Jewish students to go back to Poland. A Jewish woman at Yale was assaulted with a Palestinian flag. And an Orthodox rabbi at Columbia told students to go home for their safety. Demonstrators on these campuses shouted: Say it loud and say it clear, we don't want no Zionists here. In one chant at Columbia, the protesters were

more info


04/23/2024
The Cult of 'My Truth'
NPR is only the latest institution to fall to woke relativism.

more info


04/23/2024
House Foreign Aid Bills Put a Target on Johnson's Back
After a vote in favor of sending $95 billion to Ukraine, Israel, and Taiwan passed, far right Republicans are threatening a motion to vacate the speaker of the house.

more info


04/23/2024
Biden's Energy Policies Fueling Trump Campaign in PA
A pause on new liquefied natural gas projects has angered the shale gas industry in a critical election swing state

more info



Custom Search

More Politics Articles:

Related Articles

Senate Drug Plan Helps Government, Hurts Patients


Nancy Pelosi has a plan to lower drug prices. The Speaker of the House just released a new bill that would impose a slew of new taxes and allow the government to meddle with private businesses.

So-Called Methane Regulation "Rollbacks" Actually Reduce Emissions


President Trump just proposed a small update to methane-emission regulations. But judging by the Democratic candidates' hyperbolic reactions, you'd think he personally assaulted Mother Earth.

A Time of Civility Needed Again


Tonight, President Donald Trump will visit Minneapolis. Minneapolis Mayor Jacob Frey stated, "While there is no legal mechanism to prevent the president from visiting, his message of hatred will never be welcome in Minneapolis." For those too young to remember, the United States in 1963 was divided deeply over the growing civil rights movement—a division that later widened with the war in Vietnam.

Betsy Ross Recall is a Cheap Moral Stand


Nike courted controversy when it cancelled a new line of Betsy Ross flag-stitched sneakers just before the Fourth of July. The American shoemaker, valued at over $130 billion, pulled the shoes after former NFL quarterback and company spokesperson Colin Kaepernick worried on Twitter that the flag was a racist symbol.

Jordan B. Peterson: A Sign of the End Times?


It is not often that a clinical psychologist becomes the cultural equivalent of a rock star, but Canadian academic Jordan B. Peterson has done just that. Cometh the hour, cometh the man, as the old saying goes, and Dr. Peterson is surely a man who has found his time. And all indications are that, behind his characteristically serious (if not slightly puzzled) expression, he quite enjoys the irritation and annoyance that his forthright statements on our current cultural climate cause the self-appointed members of contemporary Committees of Public Safety. Like Camille Paglia (who provided a jacket commendation for his latest book) he preaches that most unpopular of gospels in this age of victimhood: personal responsibility.

Direct-to-Consumer Drug Advertising Benefits Companies, but Patients Even More


Analysts at the nonpartisan Congressional Budget Office recently scored Speaker Nancy Pelosi's drug pricing bill, H.R. 3.

Sharp Cuts to Research Funding Would Deprive Patients of Hope


Congress is poised to pass two separate bills designed to bring down drug prices.

America Shows How to Fight Climate Change Without Regulation


Speaking at the United Nations in December, House Speaker Nancy Pelosi drew cheers by saying the United States was "still in" the Paris Climate Agreement.

Trump's New Drug Pricing Plan Isn't "The Best Deal" For Patients


President Trump will soon unveil a new plan to reduce drug prices.

The Smart and Practical Way to Address Climate Change


Lawmakers want to fight climate change, but many of them are taking the wrong approach. Proposals to abandon fossil fuels entirely, like the Green New Deal, are both impractical and expensive.

Expansion of "Buy America" Rules Would Slow Development of Coronavirus Vaccine


Federal policymakers are considering laws that would force federal agencies to rely solely on medicines made in the United States.

Costs At the PHarmacy are Spiraling, But Price Controls Are the Wrong Solution


Congress is considering two plans to reduce high drug prices. Senators Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa) have spent the past several months promoting their Prescription Drug Pricing Reduction Act. Meanwhile, Sen. Mike Crapo (R-Idaho) is pushing his alternative, the Lower Costs, More Cures Act.

U.S.-Canada Trade Must Prevail Amid Pandemic


The United States-Canada border has been closed to cross-border tourism and other non-essential travel for more than three months.

Summer 2020 COVID-19 Data in Pennsylvania: What We Don't Know


The COVID-19 coronavirus is a novel virus, and everybody who claims they have it figured out is living under an illusion. Our knowledge is growing, but it is still very fragmented. Our local politicians have been cautious because of the vast unknown; we have never been here before.

The World Can Thank President Trump for the Oil Deal


In the midst of a pandemic, President Trump was able to convince the second and third largest crude oil producing countries to voluntarily cut production. In so doing he may have saved global financial markets, the U.S. energy industry -- and the U.S. economy.